Hinge Health (HNGE)
Market Price (4/22/2026): $45.0 | Market Cap: $3.6 BilSector: Health Care | Industry: Health Care Technology
Hinge Health (HNGE)
Market Price (4/22/2026): $45.0Market Cap: $3.6 BilSector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -10% Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 51% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 29%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 28% Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Telehealth Platforms, Remote Patient Monitoring, and Wearable Health Devices. | Weak multi-year price returns2Y Excs Rtn is -21%, 3Y Excs Rtn is -52% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -546 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -93% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 109% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -19% Key risksHNGE key risks include [1] intense competition and market commoditization threatening its premium pricing position and technological advantages, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -10% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 51% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 29%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 28% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Telehealth Platforms, Remote Patient Monitoring, and Wearable Health Devices. |
| Weak multi-year price returns2Y Excs Rtn is -21%, 3Y Excs Rtn is -52% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -546 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -93% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 109% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -19% |
| Key risksHNGE key risks include [1] intense competition and market commoditization threatening its premium pricing position and technological advantages, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Analyst Price Target Reductions Reflecting Tempered Expectations.
Despite reporting strong Q4 2025 financial results, several analysts revised down their price targets for Hinge Health, signaling a more cautious outlook on the stock's near-term potential. For example, Evercore ISI trimmed its price target on Hinge Health to $45 from $50, while maintaining an Outperform rating. Similarly, Canaccord Genuity Group cut its target price from $65.00 to $53.00. These reductions indicate a reassessment of the company's valuation or growth trajectory by market experts.
2. Significant Insider Selling by a Key Executive.
A substantial insider sale by Chairman Gabriel M.I. Mecklenburg in March 2026 may have contributed to negative sentiment. On March 6, 2026, Mecklenburg sold 166,666 shares, a transaction valued at approximately $7.69 million based on the closing price of $46.14 on that day. Such a large sale by a top executive can be interpreted by investors as a lack of strong confidence in the company's future stock performance, often leading to downward pressure.
Show more
Stock Movement Drivers
Fundamental Drivers
The -4.1% change in HNGE stock from 12/31/2025 to 4/21/2026 was primarily driven by a -32.6% change in the company's P/S Multiple.| (LTM values as of) | 12312025 | 4212026 | Change |
|---|---|---|---|
| Stock Price ($) | 46.45 | 44.56 | -4.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 355 | 588 | 65.7% |
| P/S Multiple | 9.0 | 6.0 | -32.6% |
| Shares Outstanding (Mil) | 69 | 80 | -14.1% |
| Cumulative Contribution | -4.1% |
Market Drivers
12/31/2025 to 4/21/2026| Return | Correlation | |
|---|---|---|
| HNGE | -4.1% | |
| Market (SPY) | -5.4% | 18.9% |
| Sector (XLV) | -5.7% | 9.7% |
Fundamental Drivers
The -9.2% change in HNGE stock from 9/30/2025 to 4/21/2026 was primarily driven by a -39.7% change in the company's P/S Multiple.| (LTM values as of) | 9302025 | 4212026 | Change |
|---|---|---|---|
| Stock Price ($) | 49.08 | 44.56 | -9.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 335 | 588 | 75.3% |
| P/S Multiple | 10.0 | 6.0 | -39.7% |
| Shares Outstanding (Mil) | 69 | 80 | -14.1% |
| Cumulative Contribution | -9.2% |
Market Drivers
9/30/2025 to 4/21/2026| Return | Correlation | |
|---|---|---|
| HNGE | -9.2% | |
| Market (SPY) | -2.9% | 16.4% |
| Sector (XLV) | 5.3% | 4.3% |
Fundamental Drivers
nullnull
Market Drivers
3/31/2025 to 4/21/2026| Return | Correlation | |
|---|---|---|
| HNGE | ||
| Market (SPY) | 16.3% | 21.9% |
| Sector (XLV) | 1.3% | 2.2% |
Fundamental Drivers
nullnull
Market Drivers
3/31/2023 to 4/21/2026| Return | Correlation | |
|---|---|---|
| HNGE | ||
| Market (SPY) | 63.3% | 21.9% |
| Sector (XLV) | 18.0% | 2.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| HNGE Return | - | - | - | - | 24% | -5% | 17% |
| Peers Return | -46% | -65% | -39% | -63% | -28% | -4% | -97% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 4% | 89% |
Monthly Win Rates [3] | |||||||
| HNGE Win Rate | - | - | - | - | 50% | 50% | |
| Peers Win Rate | 31% | 25% | 44% | 33% | 28% | 42% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| HNGE Max Drawdown | - | - | - | - | -7% | -33% | |
| Peers Max Drawdown | -53% | -68% | -59% | -71% | -58% | -31% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TDOC, AMWL, DRIO.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/21/2026 (YTD)
How Low Can It Go
HNGE has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -16.1% | -25.4% |
| % Gain to Breakeven | 19.1% | 34.1% |
| Time to Breakeven | 599 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -28.8% | -33.9% |
| % Gain to Breakeven | 40.4% | 51.3% |
| Time to Breakeven | 116 days | 148 days |
| 2018 Correction | ||
| % Loss | -15.8% | -19.8% |
| % Gain to Breakeven | 18.8% | 24.7% |
| Time to Breakeven | 326 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -40.6% | -56.8% |
| % Gain to Breakeven | 68.3% | 131.3% |
| Time to Breakeven | 1,100 days | 1,480 days |
Compare to TDOC, AMWL, DRIO
In The Past
SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Hinge Health (HNGE)
AI Analysis | Feedback
- Digital Musculoskeletal (MSK) Care Service: A comprehensive, AI-powered virtual program that provides personalized and largely automated care for joint and muscle health, spanning prevention, acute injury, chronic pain, and post-surgical rehabilitation.
- TrueMotion AI-powered Motion Tracking Technology: An integrated technology within their service that utilizes AI for real-time exercise feedback and tracks member progress, enabling scalable and personalized therapy.
- Enso Electrical Nerve Stimulation Wearable Device: A proprietary, FDA-cleared wearable device seamlessly integrated into the service, delivering non-addictive and non-invasive pain relief via electrostimulation.
AI Analysis | Feedback
Hinge Health (HNGE) primarily sells to other companies.
The company's major customers are:
- Self-insured employers, including many of the nation’s leading enterprises across a broad range of industries and sizes. As of December 31, 2024, Hinge Health had active client agreements with 49% of the Fortune 100 companies and 42% of the Fortune 500 companies.
- Public sector self-insured employers, such as state and local city governments and labor unions.
While Hinge Health partners with major national health plans and PBMs to facilitate access to clients, and is expanding to serve health plans' fully-insured and Medicare Advantage populations directly, its primary clients are explicitly stated as self-insured employers.
The provided text does not list specific names of the Fortune 100, Fortune 500, or other employer clients. Therefore, specific customer company names and their symbols cannot be provided.
AI Analysis | Feedback
nullAI Analysis | Feedback
Daniel Perez, Co-Founder and Chief Executive Officer
Daniel Perez co-founded Hinge Health in 2014. He holds a B.S. in Biology from Westminster University and completed a DPhil (PhD) in Biochemistry from the University of Oxford. Prior to Hinge Health, he co-founded Marblar and the Oxbridge Biotech Roundtable. He was inspired to start Hinge Health with Gabriel Mecklenburg due to their personal experiences with musculoskeletal injuries.
James Budge, Chief Financial Officer
James Budge joined Hinge Health as Chief Financial Officer in March 2023. He brings 25 years of CFO experience across various public and private high-growth technology companies. His previous CFO roles include Automation Anywhere, Pluralsight, Anaplan, Genesys Cloud Services, and Rovi Corporation. Budge has a track record of raising capital, taking companies public, and overseeing numerous acquisitions. He holds a B.S. in Accounting from Brigham Young University. His career has involved accelerating growth for public and late-stage private companies.
Gabriel Mecklenburg, Co-Founder and Executive Chairman
Gabriel Mecklenburg is the Co-Founder and Executive Chairman of Hinge Health, having also served as Chief Operating Officer from October 2014 to February 2021. He co-founded Marblar and Oxbridge Biotech Roundtable Ltd. He holds an M.Sc. in Materials Science from the University of Cambridge and an M. Phil. in Bioengineering from Imperial College London.
Jim Pursley, President
Jim Pursley has served as President of Hinge Health since March 2021. Before joining Hinge Health, he was the Chief Commercial Officer of Livongo Health. He also held various executive positions at Care Innovations and GE HealthCare Technologies. He earned an M.B.A. from Kellogg School of Management at Northwestern University and a B.S. in Management Science and Information Systems from Pennsylvania State University.
Dr. Jeff Krauss, Chief Medical Officer
Dr. Jeff Krauss is the Chief Medical Officer at Hinge Health, a role he assumed in September 2018.
AI Analysis | Feedback
The key risks to Hinge Health's business include:
- Challenges with Healthcare Reimbursement and Regulatory Environment: Hinge Health's business model relies on developing "novel billing methods" and partnering with various entities like health plans and pharmacy benefit managers (PBMs) to navigate the complex healthcare reimbursement framework. The healthcare industry is heavily regulated, and any changes to reimbursement policies, challenges in gaining acceptance for their billing methods, or difficulties in expanding into new, highly regulated segments like fully-insured and Medicare Advantage populations and federal insurance plans, could significantly impact their revenue and growth trajectory.
- Dependence on AI-Powered Technology Efficacy and Member Engagement: Hinge Health's core value proposition is built on its AI-powered motion tracking technology (TrueMotion) and proprietary FDA-cleared wearable device (Enso), which largely automate care for joint and muscle health and aim to reduce human care team hours by approximately 95%. A significant risk lies in the continuous efficacy of these technologies in delivering superior clinical outcomes, maintaining high member satisfaction, and sustaining member engagement, particularly given the inherent difficulty of automating unstructured physical tasks in healthcare. Any technical failures, lack of desired clinical results, or a decline in member trust and adoption could undermine the company's value proposition.
- Intense Competition and Market Penetration Challenges: While Hinge Health operates in a "massive" musculoskeletal (MSK) market, the healthcare industry has "no shortage of new technologies," implying a highly competitive landscape. Despite significant client retention rates and contracts with a large percentage of Fortune 100 and 500 companies, Hinge Health's current contracted lives represent only 5% of its total addressable market. The company faces the ongoing challenge of effectively competing with existing solutions and new market entrants, and efficiently penetrating the remaining 95% of the market to sustain its growth.
AI Analysis | Feedback
null
AI Analysis | Feedback
The addressable market for Hinge Health's main products and services, which include its digital musculoskeletal (MSK) care platform, is approximately 400 million lives in the U.S.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for Hinge Health (HNGE)
Hinge Health anticipates several key drivers for its revenue growth over the next 2-3 years, primarily stemming from its extensive market opportunity, strategic partnerships, and expansion into new customer segments.- Growth in contracted lives and client acquisition: Hinge Health currently serves approximately 20 million contracted lives, which represents only 5% of its total addressable market. This leaves substantial room for growth through acquiring new self-insured employers and increasing penetration within the Fortune 100 and Fortune 500 companies, where it already has significant presence but still opportunities to expand.
- Expansion into new market segments: The company is in the early stages of broadening its reach beyond self-insured employers to serve fully-insured and Medicare Advantage populations of health plans, as well as federal insurance plans. This strategic expansion into new payer types opens up large, previously untapped revenue streams.
- Deepening engagement and penetration within existing client base: Hinge Health benefits from a recurring revenue model, demonstrated by a net dollar retention of 117% as of December 31, 2024, and a 12-month client retention rate of 98%. This indicates a strong ability to enroll, engage, and re-engage eligible members within its existing client contracts, leading to organic revenue growth over the typical three-year contract term.
- Leveraging and expanding its partner network: With over 50 partners, including the five largest national health plans and top three PBMs, Hinge Health's partner network is a crucial component of its efficient go-to-market strategy. These partnerships reduce friction in contracting, procurement, and onboarding, facilitating the efficient provision of its platform to clients and members, thereby accelerating client acquisition and growth in contracted lives.
AI Analysis | Feedback
nullLatest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Hinge Health Stock (+17%): Earnings Beat & AI Narrative Ignite Rally | 02/12/2026 | |
| Hinge Health Earnings Notes | 12/20/2025 | |
| Can Hinge Health Stock Hold Up When Markets Turn? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to HNGE.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 6.79 |
| Mkt Cap | 0.6 |
| Rev LTM | 419 |
| Op Inc LTM | -134 |
| FCF LTM | 56 |
| FCF 3Y Avg | -32 |
| CFO LTM | 73 |
| CFO 3Y Avg | -32 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -1.8% |
| Rev Chg 3Y Avg | -3.4% |
| Rev Chg Q | -10.9% |
| QoQ Delta Rev Chg LTM | -2.9% |
| Op Inc Chg LTM | 29.1% |
| Op Inc Chg 3Y Avg | 11.6% |
| Op Mgn LTM | -67.6% |
| Op Mgn 3Y Avg | -62.0% |
| QoQ Delta Op Mgn LTM | 2.4% |
| CFO/Rev LTM | -7.4% |
| CFO/Rev 3Y Avg | -44.6% |
| FCF/Rev LTM | -10.5% |
| FCF/Rev 3Y Avg | -48.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.6 |
| P/S | 1.3 |
| P/Op Inc | -3.9 |
| P/EBIT | -3.2 |
| P/E | -3.3 |
| P/CFO | 1.0 |
| Total Yield | -51.8% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -82.6% |
| D/E | 0.3 |
| Net D/E | 0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 7.5% |
| 3M Rtn | 3.0% |
| 6M Rtn | -20.6% |
| 12M Rtn | -9.9% |
| 3Y Rtn | -81.8% |
| 1M Excs Rtn | -1.1% |
| 3M Excs Rtn | -1.0% |
| 6M Excs Rtn | -25.6% |
| 12M Excs Rtn | -44.6% |
| 3Y Excs Rtn | -151.4% |
Price Behavior
| Market Price | $44.56 | |
| Market Cap ($ Bil) | 3.6 | |
| First Trading Date | 05/22/2025 | |
| Distance from 52W High | -26.4% | |
| 50 Days | 200 Days | |
| DMA Price | $41.06 | $41.06 |
| DMA Trend | indeterminate | down |
| Distance from DMA | 8.5% | 8.5% |
| 3M | 1YR | |
| Volatility | 64.0% | 65.3% |
| Downside Capture | 0.05 | 0.69 |
| Upside Capture | 67.28 | 149.36 |
| Correlation (SPY) | 14.8% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.31 | 0.79 | 0.87 | 0.73 | 0.35 | 0.30 |
| Up Beta | -5.88 | -2.47 | -1.69 | -0.27 | -0.04 | -0.65 |
| Down Beta | 0.63 | 3.20 | 1.58 | 0.32 | -0.36 | -0.55 |
| Up Capture | 62% | 114% | 81% | 87% | 106% | 13% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 10 | 22 | 31 | 61 | 102 | 102 |
| Down Capture | 86% | 8% | 127% | 129% | 110% | 68% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 12 | 20 | 32 | 65 | 108 | 108 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HNGE | |
|---|---|---|---|---|
| HNGE | 23.0% | 65.4% | 0.61 | - |
| Sector ETF (XLV) | 9.2% | 16.0% | 0.37 | 1.8% |
| Equity (SPY) | 23.7% | 12.7% | 1.52 | 21.6% |
| Gold (GLD) | 41.4% | 27.5% | 1.25 | -0.4% |
| Commodities (DBC) | 22.4% | 16.2% | 1.25 | -3.3% |
| Real Estate (VNQ) | 14.2% | 13.8% | 0.72 | 11.0% |
| Bitcoin (BTCUSD) | -10.4% | 42.7% | -0.14 | 11.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HNGE | |
|---|---|---|---|---|
| HNGE | 4.2% | 65.4% | 0.61 | - |
| Sector ETF (XLV) | 5.9% | 14.6% | 0.22 | 1.8% |
| Equity (SPY) | 10.8% | 17.1% | 0.49 | 21.6% |
| Gold (GLD) | 21.6% | 17.8% | 0.99 | -0.4% |
| Commodities (DBC) | 10.9% | 18.8% | 0.47 | -3.3% |
| Real Estate (VNQ) | 4.1% | 18.8% | 0.12 | 11.0% |
| Bitcoin (BTCUSD) | 3.8% | 56.4% | 0.29 | 11.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HNGE | |
|---|---|---|---|---|
| HNGE | 2.1% | 65.4% | 0.61 | - |
| Sector ETF (XLV) | 9.5% | 16.5% | 0.47 | 1.8% |
| Equity (SPY) | 13.9% | 17.9% | 0.67 | 21.6% |
| Gold (GLD) | 13.7% | 15.9% | 0.71 | -0.4% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | -3.3% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.23 | 11.0% |
| Bitcoin (BTCUSD) | 68.0% | 66.9% | 1.07 | 11.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 2/10/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Revenue | 171.00 Mil | 172.00 Mil | 173.00 Mil | 10.3% | Higher New | Guidance: 156.00 Mil for Q4 2025 | |
| Q1 2026 Non-GAAP Income from Operations | 30.00 Mil | 31.00 Mil | 32.00 Mil | -11.4% | Lower New | Guidance: 35.00 Mil for Q4 2025 | |
| Q1 2026 Non-GAAP Operating Margin | 18.0% | ||||||
| 2026 Revenue | 732.00 Mil | 737.00 Mil | 742.00 Mil | 28.6% | Higher New | Guidance: 573.00 Mil for 2025 | |
| 2026 Non-GAAP Income from Operations | 151.00 Mil | 153.50 Mil | 156.00 Mil | 43.5% | Higher New | Guidance: 107.00 Mil for 2025 | |
| 2026 Non-GAAP Operating Margin | 21.0% | ||||||
Prior: Q3 2025 Earnings Reported 11/4/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q4 2025 Revenue | 155.00 Mil | 156.00 Mil | 157.00 Mil | ||||
| Q4 2025 Non-GAAP Income from Operations | 34.00 Mil | 35.00 Mil | 36.00 Mil | ||||
| 2025 Revenue | 572.00 Mil | 573.00 Mil | 574.00 Mil | 4.2% | Raised | Guidance: 550.00 Mil for 2025 | |
| 2025 Non-GAAP Income from Operations | 106.00 Mil | 107.00 Mil | 108.00 Mil | 33.8% | Raised | Guidance: 80.00 Mil for 2025 | |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Perez, Daniel Antonio | CEO & Co-Founder | Direct | Sell | 1062026 | 46.38 | 166,665 | Form | ||
| 2 | Pursley, James | President | Direct | Sell | 12232025 | 48.40 | 15,000 | 725,950 | 37,254,715 | Form |
| 3 | Budge, James | Chief Financial Officer | Direct | Sell | 12232025 | 48.41 | 10,491 | 507,837 | 21,355,866 | Form |
| 4 | Perez, Daniel Antonio | CEO & Co-Founder | Direct | Sell | 12162025 | 48.53 | 166,670 | Form | ||
| 5 | Robinson, Elliott | See footnote | Sell | 12092025 | 0.00 | 0 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.